CD4 and neoplasm: Within the tumor microenvironment, we found that inhibition of TLR1/2 by the small molecule CU-CPT22 dramatically decreased the effect of OXP, leading to fewer tumor-infiltrating immune cells, including CD4+, CD8+ and IFNγ+ CD8+ cells.